Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Total Non-Current Liabilities for 3 consecutive years, with $517.0 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 18.59% year-over-year to $517.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $517.0 million (up 18.59% YoY) and the FY2025 annual result came in at $517.0 million, up 35.21% from the prior year.
• Total Non-Current Liabilities climbed to $517.0 million in Q4 2025 per TLX's latest filing, from $436.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for TLX reached as high as $517.0 million in Q4 2025 and fell as low as $65.0 million in Q4 2023.
• A 3-year average of $339.3 million and a median of $436.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 571.11% — and 2025, when it advanced 18.59%.
• Year by year, Total Non-Current Liabilities stood at $65.0 million in 2023, then surged by 571.11% to $436.0 million in 2024, then grew by 18.59% to $517.0 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $517.0 million, $436.0 million, and $65.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.